Molecular Infectious Disease Testing Market worth $19.09 billion by 2031
The report "Molecular Infectious Disease Testing Market by Product & Service (Kits, Instruments), Type (Singleplex, Multiplex), Test Type (Lab, PoC), Disease (STD, Flu, GI, HAI), Technology (PCR, NGS), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2031", is projected to grow from USD 11.30 billion in 2026 and to reach USD 19.09 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 11.1% during the forecast period.
Browse 550 market data Tables and 70 Figures spread through 500 Pages and in-depth TOC on "Molecular Infectious Disease Testing Market by Product & Service (Kits, Instruments), Type (Singleplex, Multiplex), Test Type (Lab, PoC), Disease (STD, Flu, GI, HAI), Technology (PCR, NGS), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/molecular-infectious-disease-testing-market-40667482.html
The molecular infectious disease testing market is rapidly expanding, driven by the rising prevalence of infectious diseases worldwide. The rising number of cases of diseases such as HIV, influenza, and hepatitis, along with the emergence of new infections, is driving the demand for more accurate and efficient diagnostic solutions. Additionally, there is growing interest in research and development in molecular diagnostics, leading to the development of more advanced and precise testing technologies.
Increased investments in research & development, paired with advancements in molecular testing, have significantly accelerated progress in this area, enabling the development of effective detection methods. Breakthroughs in technology, particularly in multiplex testing, PCR, and next-generation sequencing, are expected to further accelerate market growth.
“By technology, the PCR segment accounted for the largest share of the market in 2025.”
By technology, the molecular infectious disease testing market is segmented into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing (NGS), in situ hybridization, DNA microarrays, and other technologies. In 2025, the PCR segment was the leading technology in this market, driven by its high sensitivity and reliability in detecting various pathogens. PCR has gained widespread acceptance in molecular infectious disease testing because it is recognized as a dependable and sensitive diagnostic method. The availability of well-optimized protocols, along with high-quality commercial kits and reagents, has made PCR easier to utilize in laboratory settings. Furthermore, advancements in PCR automation have increased its efficiency, making it the preferred choice for diagnostic labs seeking fast, accurate results. The growing demand for precise, efficient testing solutions is a key factor driving the dominance of PCR in addressing the rising challenges of infectious disease management and detection.
“By end user, diagnostic laboratories are the fastest-growing end-user segment in the molecular infectious disease testing market.”
By end user, the molecular infectious disease testing market can be segmented into diagnostic laboratories, hospitals & clinics, and other end users. Currently, diagnostic laboratories represent the fastest-growing segment in this market. This growth is largely driven by rising demand for effective, accurate diagnostic procedures, as the incidence of infectious diseases has increased significantly in recent years. The growing need for precise pathogen identification has led diagnostic laboratories to adopt advanced techniques such as polymerase chain reaction (PCR), multiplex tests, and others, enabling faster pathogen identification. Furthermore, heightened focus on early disease detection, particularly during health crises, is driving the growing use of molecular diagnostics in these laboratories.
“North America is the largest regional market for molecular infectious disease testing.”
The molecular infectious diseases testing market has been segmented into six key geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC Countries. In 2025, North America held the largest share of the molecular infectious disease testing market, attributed to its advanced healthcare infrastructure and easy access to innovative technologies. Furthermore, improved surveillance systems and outbreak management strategies have enhanced the region's capacity to respond to the burden of infectious diseases, thereby increasing demand for innovative molecular diagnostic tests. Additionally, the contributions of major companies, robust regulatory policies, and significant investments in healthcare innovations have played a critical role in maintaining North America's dominance in this market.
The major players operating in this market are Danaher (US), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Becton, Dickinson and Company (US), and QuidelOrtho Corporation (US), among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Molecular Infectious Disease Testing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
